Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Updated . What changed?
Kiromic BioPharma, Inc is a biotechnology business based in the US. Kiromic BioPharma shares (KRBP) are listed on the NASDAQ and all prices are listed in US Dollars. Kiromic BioPharma employs 11 staff and has a market cap (total outstanding shares value) of USD$79.3 million.
|52-week range||USD$8.01 - USD$12.11|
|50-day moving average||USD$9.2601|
|200-day moving average||USD$9.3915|
|Wall St. target price||N/A|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$0|
|Return on assets TTM||0%|
|Return on equity TTM||0%|
|Market capitalisation||USD$79.3 million|
TTM: trailing 12 months
There are currently 4,722 Kiromic BioPharma shares held short by investors – that's known as Kiromic BioPharma's "short interest". This figure is 42.9% up from 3,305 last month.
There are a few different ways that this level of interest in shorting Kiromic BioPharma shares can be evaluated.
Kiromic BioPharma's "short interest ratio" (SIR) is the quantity of Kiromic BioPharma shares currently shorted divided by the average quantity of Kiromic BioPharma shares traded daily (recently around 26233.333333333). Kiromic BioPharma's SIR currently stands at 0.18. In other words for every 100,000 Kiromic BioPharma shares traded daily on the market, roughly 180 shares are currently held short.
To gain some more context, you can compare Kiromic BioPharma's short interest ratio against those of similar companies.
However Kiromic BioPharma's short interest can also be evaluated against the total number of Kiromic BioPharma shares, or, against the total number of tradable Kiromic BioPharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Kiromic BioPharma's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Kiromic BioPharma shares in existence, roughly 0 shares are currently held short) or 0.0014% of the tradable shares (for every 100,000 tradable Kiromic BioPharma shares, roughly 1 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Kiromic BioPharma.
Find out more about how you can short Kiromic BioPharma stock.
We're not expecting Kiromic BioPharma to pay a dividend over the next 12 months.
You may also wish to consider:
Kiromic BioPharma, Inc., a target discovery and gene editing company, focuses on developing immuno-oncology therapeutics for the treatment of blood cancers and solid tumors. Its product portfolio include ALEXIS AIDT-1, an allogenic CAR cell product candidate targeting AIDT-1; ALEXIS AIDT-2 EOC, an allogenic CAR cell product candidate targeting AIDT-2; ALEXIS AIDT-2 MPM (malignant pleural mesothelioma), an allogenic CAR/NKT-Like cell product candidate targeting AIDT-2; and PD-1-AR, a check point inhibitor for solid tumors, as well as oral healthcare products, such as mouthwash. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.